The use of Rimonabant as a treatment to aid obesity is receiving much interest within its users and dieticians as well. It is the only medicine that can be used for a long term treatment of obesity and is found to be very safe and promising in its attitude. It is an anorectic anti-obesity drug i.e. a drug that causes loss of appetite.

This drug works completely different from other weight loss drugs. It seems to suppress weight loss in a different way. Other weight loss drugs present in the market suppresses appetite by acting as a stimulant or through an effect on neurotransmitters in the brain. But it is the first drug of its kind which blocks selective CB1 receptors. It suppresses appetite by blocking CB1 receptors on Endocannabinoid in the brain and in the fat cells of our body.

In another study, it has been found that by blocking the CB1 receptors, Rimonabant not only induces weight loss, but also significantly reduces abdominal fat in over weight and obese patients. This invariably increases the level for good HDL-cholesterol, lower triglycerides, and improves impaired levels of glucose and insulin. This reduces the risk of cardiovascular heart diseases and diabetes.

Its developers Sanofi-Aventis claim that it is also found effective in assisting smokers to quit smoking. They are currently researching to determine the possible value of Rimonabant in smoking cessation therapy. It was actually found that smokers often experience extreme hunger pangs and it has been found that Endocannabinoid system plays a critical role in body's response to tobacco dependence. Hence they claim that by inhibiting the factors responsible for activating the Endocannabinoid system, one can not only shed off extra fats but also quit smoking.

Though there is no wonder drug to deal with Obesity, but Acomplia can show some wonderful results if used properly on a regular basis. Moreover no adverse side effects are recorded till date and are tested to be mild and tolerable. However, further researches are going on to prove its efficacy and safety.